Objectives. For pharmacological reasons, the effect of the combination of MTX and SSZ may be different in RA patients who are naïve to these drugs compared to patients with an insufficient response to one of them. Therefore, we compared the results of randomized controlled trials (RCTs) on the combination of MTX and SSZ in naïve patients and in patients with an insufficient response to SSZ. Methods. A systematic literature search was performed to identify RCTs that compared the MTX-SSZ combination to either drug alone. The databases MEDLINE and the Cochrane Clinical Trials registry were searched from 1966 up to April 2007. The efficacy of the single therapeutic agents or their combination was assessed using the mean change in the disease activity score (DAS) and the ACR improvement criteria.
Introduction
MTX and SSZ are frequently used DMARDs in the treatment of RA, especially early in the disease course. Both drugs are effective, have an acceptable toxicity and their cost price is low. MTX and SSZ are used as monotherapy and in combination. Combination therapy can be started simultaneously in patients naı¨ve to both drugs, or in an add-on fashion if one of the agents does not have the desired effect. However, for pharmacological reasons, the effect of the combination of MTX and SSZ may be different between patients who are naı¨ve to these DMARDs and those who have an insufficient response to one of them.
In general, a combination of two drugs may result in effects that are: multiplicative if one drug promotes the action of the other, additive if both effects add to each other, or sub-additive if the two drugs act in competition. The effects of drugs in combination are best studied using randomized clinical trials (RCTs) with three parallel arms consisting of drugs A, B and the combination A þ B, with all randomized patients being naı¨ve to A and B (Fig. 1) . Other settings consist of RCTs with an add-on fashion. In the latter, patients with an insufficient response to drug A are randomized to continuation of drug A, switch to drug B or addition of drug B. The effect of the combination is more likely to be different in parallel trials (naı¨ve patients) than in add-on trials (drug failure) since the latter encompass a subpopulation of patients with partial or no response to one of the drugs. In an add-on trial with patients with an insufficient response to one of the study drugs, a multiplicative effect (in naı¨ve patients) may look like addition (in drug failures), an additive effect may look like sub-additivity (competition) and a sub-additive effect may look even more like competition [1] .
These theoretical interactions are often not well studied when using combinations of DMARDs in real daily practice. Since the combination of MTX and SSZ is frequently used in the therapy for RA and has been tested in several clinical trials, we chose these drugs for the present study.
The objective of this study was to review the effects of the combination of MTX and SSZ in naı¨ve patients and patients with an insufficient response, using the results of published parallel and add-on clinical trials in RA.
Materials and methods

Search strategy
To identify clinical trials for our study, a search of the electronic databases MEDLINE (OVID 1966 to April 2007), and the Cochrane Clinical Trials registry (Issue 2, 2007) was performed using the following MeSH headings (including all subheadings): 'arthritis, rheumatoid'; and 'methotrexate'; and 'sulfasalazine', combined by the operator AND. The search was limited by English as language of publication and RCT as type of study. The specific search strategy was:
combination therapy with MTX and SSZ was compared with MTX and/or SSZ monotherapy, in RA patients fulfilling the ACR 1987 revised criteria [2] . Included patients could either be naı¨ve to MTX and SSZ (parallel trials) or had failed to one of them (add-on trials). The outcome measures of the study had to be the DAS and/or the ACR response criteria. The DAS is a composite index consisting of the Ritchie articular index or joint pain count, the joint swelling count and the ESR [3] . The ACR responses are defined by at least 20, 50 and 70% improvement in joint swelling and joint tenderness counts, and three of five other variables, i.e. ESR, HAQ, pain score and assessors' and patients' global assessments [4] . Open extensions of an RCT or retrospective studies were excluded from our analysis.
Data selection
Data extracted from the studies included study characteristics (number of patients and their rate of withdrawal and follow-up duration), baseline patient characteristics (age, sex, duration of RA, proportion RF positive and baseline DAS), intervention (treatment drug, dose at baseline and during follow-up, concomitant treatment including folic or folinic acid, NSAIDs and glucocorticoids), outcome measures and adverse events. All data were extracted by one reviewer (L.G.S.). The mean change in the DAS (end value minus baseline value) for each treatment drug at the end of the study was chosen as primary outcome measure since the DAS was reported in all included studies. The proportion of patients fulfilling ACR improvement criteria at the end of the study was used as secondary outcome measure.
Data analysis
The theoretical efficacy of the MTX-SSZ combination was calculated by adding up the observed efficacies of the mean DAS changes of the single agents (MTX alone and SSZ alone) and this was then compared with the actual mean DAS change of the MTX-SSZ combination observed in the RCTs. A similar calculation was performed using the ACR responses. Furthermore, the effect sizes for MTX-SSZ combination vs monotherapy (MTX or SSZ) for change of DAS were calculated based on Cohen's D formulation of effect size. The DAS and ACR outcome measures were evaluated according to an intention to treat analysis using last observation carried forward. Data were obtained from trial results as published [5] [6] [7] [8] . In one study which only reported DAS values [8] individual patient data were available to calculate ACR responses.
Results
Search results
The current search strategy yielded a total of 44 RCTs. By screening titles and abstracts, nine articles were retrieved and selected for detailed review. After application of the inclusion criteria, five studies which described MTX and SSZ as combination therapy were excluded. The first was not an RCT but a review of another selected trial [9] . The second was an extended follow-up of another selected article and lacked data on the effects of the single DMARD therapies [10] . The third study was excluded because it was retrospective [11] . The fourth and fifth study did not match with the pre-defined study intervention, because HCQ was used as a third study medication [12] [13] . The remaining four studies were included in our analysis [5] [6] [7] [8] .
Study description
Three of the studies included were placebo-controlled, doubleblind RCTs and compared the efficacy of combined MTX and SSZ to each individual agent [5, 6, 8] . The fourth was a randomized, open study comparing the combination of MTX and SSZ with MTX alone [7] . Furthermore, two of the trials were performed with patients naı¨ve to either DMARD [6, 8] (parallel trial design) and two trials assessed the efficacy of the combination therapy in patients with a suboptimal response to SSZ [5, 7] (addon design). All trials evaluated outcome measures according to an intention to treat analysis using last observation carried forward. The proportion of patients who withdrew during follow-up varied in three studies from 19 to 28%. In the study of Haagsma et al. [7] the rate of withdrawal was low (5%). As shown in Table 1 the dosages of MTX and SSZ at baseline and at the end of the study were comparable. None of the trials allowed concomitant glucocorticoids and only one trial regarded consistent folic acid as supplementation [5] . All studies allowed a stable dose of concomitant NSAIDs.
Parallel trials
From the two parallel trials [6, 8] , the first RCT showed not only a trend to increased efficacy, but also more toxicity (nausea) of the MTX-SSZ combination compared with the single-drug arms. The second study showed comparable efficacy in all three treatment groups with a small trend in favour of the combination group, and more adverse events (nausea) in the combination group (Table 1) .
Add-on trials
The two add-on trials [5, 7] showed that the addition of MTX to SSZ in patients who had failed to the latter drug was clinically significantly superior to a switch to MTX alone, without increased toxicity. The study by Capell et al. [5] also demonstrated that the addition of MTX to SSZ was clinically significantly more effective than continuing SSZ monotherapy (Table 1) .
Comparing parallel with add-on trials
The mean changes in the DAS for the parallel trials and add-on trials are shown in Table 2 and Fig. 2 . Two RCTs with DMARDnaı¨ve patients show mean changes in the DAS for the MTX-SSZ combination of 1.3 and 1.9, respectively, which points to a subadditive effect of the combination therapy ( Fig. 2A) . On the other hand, one RCT in patients with a suboptimal response to SSZ who received MTX in an add-on fashion showed an actual mean change in the DAS of 1.1, which is close to additivity (Fig. 2B) . Unfortunately, the second add-on trial did not include a SSZ single treatment arm.
As is shown in Table 2 , there was a large effect size (1.8) for MTX-SSZ combination vs MTX monotherapy in SSZ failures in the study of Haagsma et al. 7 In the other study of SSZ failures, a smaller effect size (0.5) was found between combination therapy and monotherapy. However, the effect sizes in DMARD-naı¨ve patients were even lower since they varied between 0.1 and 0.3.
From two trials, ACR responses were available and the analysis of the latter yielded similar results to the analysis of the mean changes in the DAS (Fig. 3) . In the parallel trial with DMARDnaı¨ve patients (Fig. 3A) , ACR 20, 50 and 70 responses were achieved by 80, 33 and 3% of the patients receiving MTX-SSZ combination therapy. These effects point to sub-additivity of the combination. In the add-on trial performed in SSZ failures (Fig. 3B) , MTX-SSZ combination therapy resulted in ACR 20, 50 and 70 responses of 29, 11 and 4%, respectively, pointing to additivity.
Discussion
In this review of RCTs on MTX-SSZ combination therapy, it appeared that in MTX-SSZ-naı¨ve patients the effect of this combination was sub-additive, whereas in patients with an insufficient response to SSZ the effect of the combination was additive.
These contrasting effects may be due to differential interactions of MTX and SSZ at the pharmacodynamic or pharmacokinetic level. There are two major known pharmacodynamic interactions between these agents. First, both DMARDs have anti-inflammatory effects mediated by increased intracellular adenosine concentrations and adenosine release [14] [15] [16] . Second, both MTX and SSZ use the same cell transporter (reduced folate carrier; a folate pathway enzyme) for their intracellular uptake [17] . Further, metabolites of both SSZ and MTX are partially eliminated by renal tubular secretion [18] . However, in the study of Haagsma et al., it was shown that administration of SSZ did not influence the pharmacokinetics of MTX [7, 19] and pharmacokinetic interactions between MTX and SSZ are, therefore, unlikely [7] .
We propose that the difference in effect of the MTX-SSZ combination in naı¨ve patients and SSZ failures might be explained by pharmacodynamic interactions between both drugs. A hypothetical reason for sub-additive treatment effects may be competition of the DMARDs at the level of intracellular uptake. Both MTX and SSZ act on the reduced folate carrier but at different binding sites. Binding of SSZ to this cell transporter diminishes cellular uptake of MTX and, thus, decreased anti-inflammatory effects of MTX [17] . This could lead to sub-additive effects as was found in DMARD-naı¨ve patients. In SSZ failures, on the other hand, the cell transporter might have a diminished susceptibility for SSZ and subsequently the intracellular uptake of MTX and its efficacy will not be limited. Also, 'resistance' to SSZ may develop by an increased drug efflux as a mechanism of cellular resistance [20] leading to reduced anti-inflammatory effects of SSZ. However, this seems not to influence the efficacy of MTX [20] . Since several polymorphisms in genes of the folate pathway may be implicated in the clinical response to MTX [21, 22] or to the combination of MTX and SSZ [23] , genetic factors may also play a part in the efficacy of MTX-SSZ combination therapy. In addition, the study of Wessels et al. [24] proposed a pharmacogenetic model for predicting the clinical response of MTX treatment in RA patients. This model included gene coding for the folate pathway enzymes, which are also involved in the antiinflammatory action of SSZ [23, 25] .
In this review, the effects found in four RCTs were indirectly compared; therefore, our results might be confounded by differences in trial design or baseline characteristics. However, all RCTs analysed had similar duration and dosage schedules for MTX and SSZ, did not allow concomitant glucocorticoids, three had similar withdrawal percentages [5, 6, 8] and compliance was similar when assessed [7, 8] . The add-on study of Haagsma et al. [7] was different from the other three trials in two ways: it was performed single blind and the rate of retention was high (95%). Intention to treat analysis with last observation carried forward was used in all trials, but may have led to an underestimation of the treatment effect in the other three trials with lower retention rates. Further, this add-on trial did not include a SSZ single treatment arm. However, if this trial had included a SSZ arm, it is unlikely that the efficacy of SSZ in SSZ failures would have been larger than the efficacy of a switch to MTX, and additivity was, therefore, assumed in this trial. Not surprisingly, the baseline DAS was higher in the two RCTs performed in DMARD-naı¨ve patients, which could have increased the chance of pronounced DAS changes and to achieve synergy, but this was not the case. As expected, patients in the add-on trials had longer disease duration than those in the parallel trials. Other baseline characteristics, such as age, gender and RF were similar among the four trials.
The primary outcome measure in this study was the mean change in DAS. The ACR responses were also used as outcome measures and showed similar results as the DAS: in SSZ failures, the MTX-SSZ combination pointed to additivity and in DMARD-naı¨ve patients sub-additivity of the combination was shown. However, there was a ceiling effect for the ACR 20 response in DMARD-naı¨ve patients. As can be expected, the mean DAS changes and ACR response percentages were lower in SSZ failures than in DMARD-naı¨ve patients. This is in accordance with current evidence that treatment should be initiated in the early stages of RA in order to reduce disease activity most effectively: to achieve and sustain clinical remission [26] [27] [28] [29] .
The results of the two trials with naı¨ve patients show only minor advantage of the combination above the single components. This differs from the results of the step-down COBRA trial which showed that, in DMARD-naı¨ve patients, the combination of MTX with SSZ and prednisone was clearly superior to SSZ monotherapy, and this superiority faded when tapering the combination towards SSZ monotherapy [30] . The trials analysed in our study did not allow concomitant prednisone use; the differences might at least partly be explained by the high-dose prednisone in the COBRA trial.
The findings in the two trials with SSZ failures are different from those from the BeSt study, which demonstrated that in MTX failures the combination of MTX and SSZ had no additive therapeutic effect compared to a switch to SSZ [31, 32] . However, the design of the BeSt study was different than the studies included in our study and patients started with MTX instead of SSZ. In both strategies from the BeSt, treatment was optimized based on disease activity, which may have contributed to comparable treatment outcomes. Interestingly, based on the BeSt study and the four studies reviewed, the treatment effect of MTX-SSZ combination seems to depend on whether patients failed to MTX or to SSZ. The anti-inflammatory effect of MTX is a result of several intracellular pathways and some of them are also shared by SSZ [23, 25, 33] . It is, therefore, conceivable that blockade of MTX pathways may result in diminished anti-inflammatory effects of SSZ as well.
Our results are consistent with previous studies using triple therapy with MTX, SSZ and HCQ compared with MTX and SSZ or MTX and HCQ [12, 13] . In early RA patients naı¨ve to the study drugs, triple combination showed more efficacy, though analysis of the ACR responses again approached a sub-additive effect [13] . In patients with established RA, the triple combination was also superior to MTX alone or the combination of SSZ and HCQ and appeared to be additive [12] .
Taken together, our review indicates that in RA the combination of MTX and SSZ has sub-additive effects in patients naı¨ve to both drugs, but has additive effects in previous SSZ failures. Common pathways of MTX and SSZ may cause these different effects. Given the available evidence, addition of MTX to SSZ is a therapeutic option in SSZ failures, whereas combination of MTX and SSZ in DMARD-naı¨ve patients may not be a preferred treatment choice unless it is a COBRA scheme including high doses of glucocorticosteroids.
Rheumatology key messages
Addition of MTX to SSZ is a therapeutic option in SSZ failures. Combination of MTX and SSZ in DMARD-naïve patients has no added value unless combined with glucocorticosteroids.
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